We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00563498
First Posted: November 26, 2007
Last Update Posted: July 7, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
The University of Hong Kong
Fresienius Kabi HK Ltd
Information provided by:
Hospital Authority, Hong Kong
  Purpose
The primary purpose of this project is to investigate if addition of glutamine, an amino acid, to standard parenteral nutrition, may improve the clinical outcome of the bone marrrow transplantation reducing the occurrence of veno-occlusive disease and severity of mucositis.

Condition Intervention
Pulmonary Veno-Occlusive Disease Hepatic Veno-Occlusive Disease Mucositis Drug: Glutamine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.

Resource links provided by NLM:


Further study details as provided by Hospital Authority, Hong Kong:

Primary Outcome Measures:
  • Veno-occlusive disease [ Time Frame: 1 month ]
  • Mucositis [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Hospital stay [ Time Frame: 2 months ]
  • Use of antibiotics [ Time Frame: 2 months ]

Estimated Enrollment: 40
Study Start Date: July 2004
Estimated Study Completion Date: June 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Allogeneic bone marrow transplant recipients using busulfan and cyclophosphamide as conditioning.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00563498


Contacts
Contact: YH Leung, Dr (852) 2855 3347 ayhleung@hku.hk

Locations
China
Queen Mary Hospital Recruiting
Hong Kong, China
Sub-Investigator: YH Leung, Dr         
Sub-Investigator: Raymond Liang, Prof         
Sponsors and Collaborators
Hospital Authority, Hong Kong
The University of Hong Kong
Fresienius Kabi HK Ltd
Investigators
Principal Investigator: Albert Lie, Dr Department of Medicine/Division of Haematology, Queen Mary Hospital/ The University of Hong Kong
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00563498     History of Changes
Other Study ID Numbers: EC1432-00
HARECCTR0500034
First Submitted: November 21, 2007
First Posted: November 26, 2007
Last Update Posted: July 7, 2010
Last Verified: July 2010

Keywords provided by Hospital Authority, Hong Kong:
Veno-occlusive disease
Mucositis

Additional relevant MeSH terms:
Mucositis
Hepatic Veno-Occlusive Disease
Pulmonary Veno-Occlusive Disease
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases
Liver Diseases
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases


To Top